Donghai Wu

Dr. Donghai Wu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YZYan Zhang
Yan Zhang
XLXiao-Yu Luo
Xiao-Yu Luo
DWDonghai Wu
Donghai Wu
YXYong Xu
Yong Xu

7 January 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
TNTao Nie
Tao Nie
SZShiting Zhao
Shiting Zhao
LMLiufeng Mao
Liufeng Mao
YYYiting Yang
Yiting Yang
WSWei Sun
Wei Sun
DWDonghai Wu
Donghai Wu

13 April 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
XGXuefei Gao
Xuefei Gao
KLKuai Li
Kuai Li
HXHui Hannah Xiaoyan
Hui Hannah Xiaoyan
XKXiangping Kong
Xiangping Kong
GSGary Sweeney
Gary Sweeney
DWDonghai Wu
Donghai Wu
The adipocyte is the principal cell type for fat storage. CPT1 (carnitine palmitoyltransferase-1) is the rate-limiting enzyme for fatty acid β-oxidation, but the physiological role of CPT1 in adipocytes remains unclear. In the present study, we focused on the specific role of CPT1A in the normal functioning of adipocytes. Three 3T3-L1 adipocyte cell lines stably expressing hCPT1A (human CPT1A) cDNA, mouse CPT1A shRNA (short-hairpin RNA) or GFP (green fluorescent protein) were generated and the biological functions of these cell lines were characterized. Alteration in CPT1 activity, either by ectopic overexpression or pharmacological inhibition using etomoxir, did not affect adipocyte differentiation. However, overexpression of hCPT1A significantly reduced the content of intracellular NEFAs (non-esterified fatty acids) compared with the control cells when adipocytes were challenged with fatty acids. The changes were accompanied by an increase in fatty acid uptake and a decrease in fatty acid release. Interestingly, CPT1A protected against fatty acid-induced insulin resistance and expression of pro-inflammatory adipokines such as TNF-α (tumour necrosis factor-α) and IL-6 (interleukin-6) in adipocytes. Further studies demonstrated that JNK (c-Jun N terminal kinase) activity was substantially suppressed upon CPT1A overexpression, whereas knockdown or pharmacological inhibition of CPT1 caused a significant enhancement of JNK activity. The specific inhibitor of JNK SP600125 largely abolished the changes caused by the shRNA- and etomoxir-mediated decrease in CPT1 activity. Moreover, C2C12 myocytes co-cultured with adipocytes pre-treated with fatty acids displayed altered insulin sensitivity. Taken together, our findings have identified a favourable role for CPT1A in adipocytes to attenuate fatty acid-evoked insulin resistance and inflammation via suppression of JNK.

1 January 2017 in Cell Reports
Verified
Journal Article
Open access
BNBaoming Nie
Baoming Nie
TNTao Nie
Tao Nie
HXHui Hannah Xiaoyan
Hui Hannah Xiaoyan
PGPing Gu
Ping Gu
LMLiufeng Mao
Liufeng Mao
SDSheng Ding
Sheng Ding
Brown adipose tissue (BAT) has attracted considerable research interest because of its therapeutic potential to treat obesity and associated metabolic diseases. Augmentation of brown fat mass and/or its function may represent an attractive strategy to enhance energy expenditure. Using high-throughput phenotypic screening to induce brown adipocyte reprogramming in committed myoblasts, we identified a retinoid X receptor (RXR) agonist, bexarotene (Bex), that efficiently converted myoblasts into brown adipocyte-like cells. Bex-treated mice exhibited enlarged BAT mass, enhanced BAT function, and a modest browning effect in subcutaneous white adipose tissue (WAT). Expression analysis showed that Bex initiated several "browning" pathways at an early stage during brown adipocyte reprogramming. Our findings suggest RXRs as new master regulators that control brown and beige fat development and activation, unlike the common adipogenic regulator PPARγ. Moreover, we demonstrated that selective RXR activation may potentially offer a therapeutic approach to manipulate brown/beige fat function in vivo.

21 October 2021 in Diabetes
Verified
Journal Article
Closed access
PDF file
WSWei Sun
Wei Sun
TNTao Nie
Tao Nie
KLKuai Li
Kuai Li
WWWenjie Wu
Wenjie Wu
QLQiaoyun Long
Qiaoyun Long
HXHui Hannah Xiaoyan
Hui Hannah Xiaoyan
Background & Aims Hepatosteatosis, defined as excessive intrahepatic lipid accumulation, represents the first step of NAFLD. When combined with additional cellular stress, this benign status progresses to local and systemic pathological conditions such as NASH and insulin resistance. However, the molecular events directly caused by hepatic lipid build-up, in terms of its impact on liver biology and peripheral organs, remain unclear. Carnitine palmitoyltransferase 1A (CPT1A) is the rate limiting enzyme for long chain fatty acid beta-oxidation in the liver. Here we utilise hepatocyte-specific Cpt1a knockout (LKO) mice to investigate the physiological consequences of abolishing hepatic long chain fatty acid metabolism. Approach & Results Compared to the wild-type (WT) littermates, high fat diet (HFD)-fed LKO mice displayed more severe hepatosteatosis but were otherwise protected against diet-induced weight gain, insulin resistance, hepatic ER stress, inflammation and damage. Interestingly, increased energy expenditure was observed in LKO mice, accompanied by enhanced adipose tissue browning. RNAseq analysis revealed that the peroxisome proliferator activator alpha (PPARα)- fibroblast growth factor 21 (FGF21) axis was activated in liver of LKO mice. Importantly, antibody-mediated neutralization of FGF21 abolished the healthier metabolic phenotype and adipose browning in LKO mice, indicating that the elevation of FGF21 contributes to the improved liver pathology and adipose browning in HFD-treated LKO mice. Conclusions Liver with deficient CPT1A expression adopts a healthy steatotic status that protects against HFD-evoked liver damage and potentiates adipose browning in an FGF21-dependent manner. Inhibition of hepatic CPT1A may serve as a viable strategy for the treatment of obesity and NAFLD.

18 February 2009 in Diabetologia
Verified
Journal Article
Closed access
PDF file
XGX. F. Gao
X. F. Gao
WCW. Chen
W. Chen
XKX. P. Kong
X. P. Kong
AXA. M. Xu
A. M. Xu
ZWZ. G. Wang
Z. G. Wang
DWDonghai Wu
Donghai Wu